316eP Imiquimod-loaded dissolvable microneedles: A novel pre-clinical immunotherapeutic approach for dermato-oncology
Imiquimod, a toll-like receptor-7 agonist, is approved for topical treatment of superficial basal cell carcinoma and actinic keratosis, but dermal penetration is limited and variable. Improved delivery strategies are needed to maximise its immunotherapeutic potential in dermato-oncology. Dissolvable microneedles (MNs) provide a minimally invasive platform for intradermal administration with potential for sustained exposure. Sustained intradermal delivery may improve treatment adherence and local immune activation compared to repeated topical application.
Authors
- E. Loizidou
- A. Hyseni
- C. Russo
- T. Akmandor
- D. Leontiev
Institutions
- The London College (GB)
- University College London (GB)
- Middlesex University London (GB)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101515
- Primary Topic
- Advancements in Transdermal Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- NHS Greater Glasgow and Clyde
- NuCana
- Cancer Research UK
- University of Cambridge
- University College London
- University of Oxford
- Newcastle University
- University of Glasgow
- Cambridge University Hospitals
- Korea Health Industry Development Institute
- Oxford University Hospitals NHS Foundation Trust
- University College London Hospitals NHS Foundation Trust
- Advanced Research Projects Agency